February 8, 2021
Izzo NJ et al. Alzheimer’s Dement 2021;1–18.
Preclinical and clinical biomarker studies of CT1812:
A novel approach to Alzheimer’s disease modification
Download publication
You might also be interested by
Press Releases
CellCarta Expands its Biomarker Capabilities for Clinical Trials by adding Olink Technology to its Global Services
August 31, 2021
Proteomics/Mass Spectrometry
More infoPosters
Quantification of sBCMA in Human Plasma using a High-Throughput Hybrid IP-MRM Based Mass Spectrometry Workflow
July 27, 2021
Proteomics/Mass Spectrometry
More infoPosters
Patient Stratification using Clinical Proteomics – Validated multiplexed MRM assays to quantify HER2 and other biomarkers in clinical FFPE tissues
November 9, 2020
Proteomics/Mass Spectrometry
More infoPosters
Quantification of sBCMA in Human Plasma using a High-Throughput Mass Spectrometry Workflow for Exploratory, CAP/CLIA or Regulated Studies
November 9, 2020
Proteomics/Mass Spectrometry
More info